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I N 1979, DUCKERT reviewed the completed trials of intravenous (IV) thrombolytic ther- 
apy in acute myocardial infarction (MI) for this 
journal.’ Duckert stated in his review, “It is fair 
to conclude that today the value of thrombolytic 
treatment of acute MI has not been established.” 
Since this review, dramatic advances have been 
made in the understanding of pathogenesis of 
MI, knowledge of thrombolysis, advances in 
technology, and stratification of risk groups. 
With these advances in understanding and the 
completion of several large, prospective random- 
ization clinical trials, a much clearer picture of 
the clinical use of reperfusion therapy of MI has 
evolved. In 1979, only prolonged IV infusion of 
thrombolytic agents had been studied; since then, 
numerous other reperfusion strategies, including 
coronary bypass, intracoronary streptokinase 
infusion, short-term high-dose IV infusion of 
thrombolytic agents, and coronary angioplasty 
(PTCA), have been used. For these reasons, a 
review of the current status of reperfusion ther- 
apy is timely. The rationale and experimental 
basis for using reperfusion therapy has been 
extensively reviewed elsewhere.2-‘4 In an analysis 
of the clinical benefit of reperfusion therapy, 
three fundamental questions must be addressed. 
First, how does therapy alter the pathogenesis of 
acute MI? Second, does therapy salvage myocar- 
dium or, indirectly, does therapy preserve ven- 
tricular function? Finally, and most importantly, 
does therapy alter mortality? This review will 
examine these fundamental questions for each of 
the currently used reperfusion strategies. Before 
these questions can be addressed, an understand- 
ing of the natural history of thrombotic coronary 
occlusion, changes in ventricular function, and 
mortality must be examined. 
NATURAL HISTORY OF CORONARY 
ARTERY OCCLUSION 
Duckert stated in 1979 that “the theoretical 
basis for fibrinolytic therapy of acute infarction, 
at least to some investigators, is open to ques- 
tion.“’ This statement reflected the state of con- 
fusion that existed in the mid-1970s concerning 
the causal relationship between thrombus and 
transmural MI. Advances in clinicopathologic 
studies’5“8 have clarified the pathogenesis of MI, 
and it is now clear that thrombus plays an 
integral role in its onset. The trigger for throm- 
botic occlusion appears related to plaque fissure, 
plaque rupture, or intramural hemorrhage (Fig 
1). With endothelial disruption, cholesterol, cho- 
lesterol esters, and collagen become exposed to 
platelets and other hematologic hemostatic con- 
stituents. These events typically occur in an area 
with high-grade atherosclerotic occlusion where 
diminished coronary blood flow is present. 
Although the exact trigger for the onset of acute 
occlusion is unknown, the observations of 
Mueller et al” on the diurnal variation in fre- 
quency of onset of MI provides an intriguing 
clue. Vasospasm,‘9320 possibly related to release of 
vasoconstrictor substances from the platelets, 
may play a role in further decreasing luminal 
diameter and blood flow. Thus, circadian 
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Fig 1. Plaque fissure may evolve to reseal or progress 
to subtotal or total coronary occlusion leading to unstable 
angina or myocardial infarction. 
rhythm, stasis of blood flow, vasoconstriction, 
activation of platelets, and activation of the 
coagulation cascade combine to create a throm- 
botic occlusion. 
The actual role of thrombotic occlusion was 
greatly debated in the late 1960s and 1970s.” In 
fact, the uncertainty concerning the role of 
thrombotic occlusion led to the uncertainty 
alluded to by Duckert concerning the value of 
thrombolytic therapy. If thrombus was merely a 
passive, secondary phenomenon that occurred in 
a highly stenosed segment of a coronary artery, 
the value of thrombolytic therapy in reestab- 
lishing blood flow would be limited. Histopatho- 
logic observations and postmortem angiogra- 
phy 18~22~23 greatly clarified the primary role of 
thrombotic occlusion. Ultimately, arteriography 
during acute MI established the clear role of 
thrombotic occlusion. Recently, coronary angios- 
copyz4 corroborated these arteriographic find- 
ings. The pioneering work of DeWood et al*’ 
established that coronary angiography could be 
safely performed early in acute MI, and that a 
high incidence of complete occlusion of the 
infarct-related artery existed.26 Only a brief time 
elapsed from the demonstration of the presence 
of occluding thrombus to the pioneering work of 
Chazov et al” and Rentrop et al.28 Rentrop et al 
demonstrated that occlusive thrombus could be 
penetrated with a guidewire, then later that 
thrombus could be lysed with intracoronary 
streptokinase administration.30 Several con- 
trolled trials of intracoronary streptokinase have 
now been completed. These trials allow further 
corroboration of the initial angiographic studies 
of DeWood et al. 
CORONARY ANATOMY DURING 
TRANSLUMINAL INJURY 
Before reviewing the angiographic findings, it 
must be emphasized that all intracoronary strep- 
tokinase reperfusion trials included patients with 
clearly defined symptom onset and with ST 
segment elevation, suggesting transmural injury 
by ECG criteria. The role of occlusive thrombus, 
the coronary anatomy, and initial ventricular 
function in patients with ST segment depression 
suggesting subendocardial injury or ischemia has 
not been fully defined.3’ 
The incidence of total coronary occlusion var- 
ies with the duration of symptoms and use of IV 
heparin.32-40 When arteriography is performed in 
patients with transmural injury within five hours 
of symptom onset, over 80% of the patients will 
have an occluded infarct-related artery (Fig 2). 
At six to 24 hours from onset of symptoms, 65% 
of the vessels remain occluded. Gibson et al32 
performed coronary angiography in 154 patients 
with R-wave infarction, 11 + three days after 
admission. Therapeutic anticoagulation was not 
used in this trial and 75% of the infarct arteries 
were occluded. In a long-term study, Pichard et 
al performed angiography on 39 patients 2 to 8 
weeks after MI and found 80% of the infarct- 
related arteries to be totally occluded.33 The New 
York University-Mount Sinai reperfusion 
study34 and the Netherlands Interuniversity 
tria135 treated control groups with continuous IV 
heparin. In the former study, only 23% of the 
infarct arteries were occluded at angiography ten 
to 14 days after admission. In the later study, 
48% of the arteries were occluded in the recuper- 
ation phase. These studies demonstrate that a 
dynamic process of occlusion, spontaneous 
thrombolysis, and reocclusion commonly occurs 
during the first month after MI. Therapeutic 
anticoagulation enhances long-term patency. 
Without specific therapy, over 75% of the 
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Fig 2. Prevalence of total coronary artery occlusion during Ml. Time after symptom onset at which patients underwent 
angiography is depicted.26”24 
infarct-related arteries will be occluded in the 
convalescence phase of acute MI. With this 
knowledge of the natural history of coronary 
occlusion, the acute and chronic results of reper- 
fusion strategies can be more critically evalu- 
ated. 
In addition to determining the prevalence of 
total occlusion, Stadius et al carefully character- 
ized the coronary anatomy of the 250 patients 
enrolled in the Western Washington Intracoron- 
ary Streptokinase trial?’ To be enrolled in this 
study, patients were required to have ST- 
segment elevation of 0.15 mV in two or more 
ECG leads and present within 12 hours of symp- 
tom onset. Coronary angiography was performed 
on an average of 4.1 hours after symptom onset. 
The infarct artery was the left anterior descend- 
ing (LAD) (47%), right coronary artery (RCA) 
(45%), and circumflex (8%). In patients with 
LAD occlusion, 67.5% of the occlusions were in 
the proximal LAD and 30.7% of the occlusions 
were in the mid-LAD. In patients with RCA 
occlusion, 57.7% of the occlusions occurred prox- 
imally, 48.7% occurred in the midportion, and 
3.6% occurred in the distal portion. Since ECG 
ST elevation was required for entry into this 
study, and the posterolateral surface is often not 
accompanied by these changes, only 8% of the 
patients had circumflex occlusion, Thus, coro- 
nary occlusion occurred in the proximal or mid- 
portion of the major epicardial branches in over 
90% of the patients. A further important finding 
was that angiographic collaterals were much 
more common in RCA occlusions (58%) than in 
LAD occlusions (3 1%); P < .05. This finding 
may partially explain the following differences in 
clinical outcome between RCA and LAD occlu- 
sions. 
NATURAL HISTORY OF CHANGES IN 
VENTRICULAR FUNCTION DURING 
MYOCARDIAL INFARCTION 
With the knowledge that thrombotic coronary 
occlusion was present early in acute MI, a ration- 
ale for thrombolytic therapy existed. It was 
hoped that timely coronary reperfusion could 
interrupt the infarction and salvage myocar- 
dium. The most widely used parameter of myo- 
cardial salvage has been the change in global and 
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regional left ventricular wall motion. Despite the 
known limitations of ventricular imaging tech- 
niques in quantifying myocardial &hernia and 
infarction4’ changes in systolic function are 
widely used. Changes in ventricular wall motion 
have been widely used because these measures 
are standardized, widely available, and have 
prognostic value. 
In order to adequately assess the changes in 
ventricular function with reperfusion therapy, 
the changes occurring without this therapy must 
be examined. Wackers et a14’ examined the 
changes in radionuclide ejection fraction (EF) 
occurring during the first 24 hours of admission. 
Spontaneous changes in EF occurred in 19 of 34 
patients with improvement in 11 patients and 
deterioration in eight. These investigators postu- 
lated that changes in sympathetic tone that occur 
early in acute MI might account for the early 
changes in ventricular function. Raizner et a14’ 
and Schreiber et a144 measured serial global EF 
24 hours after admission and predischarge in 
patients treated conventionally. No serial 
changes in mean global EF were found in either 
study. Similarly, Tamaki et a145 found no change 
in serial global EF in 95 patients studied at 24 
hours and day 10. Coromilas et a146 reported in 
preliminary fashion serial radionuclide EF in 87 
acute MI patients treated conservatively. No 
difference in EF occurred between days 1 and 3 
and predischarge in this study. In contradistinc- 
tion, regional wall motion has great variability 
between day 1 and day 10 post-MI. In the study 
of Tamaki et al, 30% of the severely hypokinetic 
segments changed (25% improved, 5% deterio- 
rated). Improvement in at least one hypokinetic 
or akinetic segment was seen in 47% of these 
patients. 
Shelbert et a147 evaluated changes in ventricu- 
lar function occurring after hospital discharge in 
43 patients. Serial radionuclide ventriculograms 
were obtained within five days of admission and 
subsequently, 2 to 39 months (mean, 19.9 
months) later. In this study, EF increased from 
0.45 + 0.02 to 0.49 f 0.01 (P < .Ol). EF 
increased in 61%, decreased in 23%, and 
remained unchanged in only 16% of the 
patients. 
The spontaneous variability of systolic ventric- 
ular function must be considered in the design 
and interpretation of reperfusion trials that use 
changes in ventricular function as an endpoint. 
This spontaneous variability may account for the 
conflicting results found in the early, noncon- 
trolled reperfusion trials. Greatest variability in 
global and regional function occurs during the 
first 24 hours of admission, when hemodynamic 
changes, changes in sympathetic tone, and fre- 
quent administration of vasoactive agents occur. 
Least variability occurs in serial global EF mea- 
surements at 24 hours and predischarge. Even in 
this time interval, 25% of the dysynergic seg- 
ments will spontaneously improve. 
A number of mechanisms can explain the 
spontaneous improvement in EF. Ong et a148 
elegantly demonstrated that spontaneous im- 
provement in wall motion may occur because of 
spontaneous recanalization of totally occluded 
vessels. Creatinine-Kinase Myocardial Band lev- 
els were measured serially in 34 patients with 
transmural ECG injury current. Patients who 
had early CK-MB release suggestive of sponta- 
neous recanalization improved EF from 0.38 -c 
0.09 to 0.48 * 0.08 (P < .OOl). No improvement 
in EF occurred for patients with delayed CK-MB 
release. In an angiographically controlled study, 
Schwartz et a149 found significant increases in EF 
in patients who presented with subtotal coronary 
occlusion or those with well-developed coronary 
collaterals. De Feyter et a15’ found that the 
spontaneous improvement in EF in patients with 
subtotal occlusion was equal to that achieved by 
streptokinase-induced coronary recanalization. 
Furthermore, Blanke et al” found that patients 
with subtotal coronary occlusion had a signifi- 
cantly higher initial EF than those with complete 
occlusion. 
While spontaneous reperfusion, subtotal oc- 
clusion, and extensive angiographic collaterals 
allow for improved ventricular function, the pres- 
ence of high-grade residual lesions may prevent 
improvement. Guerci et a15’ and Resenheck et 
a153 performed angioplasty in patients with 
patent infarct arteries and a high-grade residual 
stenosis three days and 3 to 5 months post-MI, 
respectively. Exercise EF improved in the study 
of Guerci et al and rest EF improved in the study 
of Resenheck et al. Since angioplasty was per- 
formed late after symptom onset, myocardial 
salvage could not be the mechanism for improved 
ventricular function. Rather, these critical coro- 
nary lesions must prevent adequate return of 
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coronary blood flow to ischemic, but viable, 
myocardial segments. 
Although spontaneous reperfusion may allow 
for improved ventricular function, Blanke et a15’ 
also found that those patients with persistent 
total occlusion and no collateral flow had 
10.1% f 7.5% decrease in absolute EF on serial 
contrast ventriculography. Rogers et als4 con- 
firmed that a significant decrease in EF occurs in 
patients with persistent total occlusion and no 
collateral flow. 
A final major confounding influence on corre- 
lation between changes in ventricular function 
and salvage of myocardium is prolonged, post- 
ischemic “stunning” of the myocardium.55 
Experimental studies demonstrated that days or 
week?’ may be required for full return of 
myocardial function after reperfusion. Hinohara 
et als8 and Erbel et als9 demonstrated that further 
improvement in ventricular function occurs up to 
3 to 9 months after hospital discharge in patients 
successfully reperfused by PTCA. 
Recognition of the apparent prognostic value 
of these measures led to the impetus to determine 
ventricular function after MI. Schultze et al first 
demonstrated6’ that those patients with poor EF 
and complex ventricular ectopy were the highest- 
risk subgroup for sudden death in the year after 
recuperation from acute MI. Sanz et a16’ 
extended these observations to 259 consecutive 
patients undergoing cardiac catheterization 1 
month after acute MI. Cox regression analysis of 
clinical and angiographic variables revealed that 
EF, the number of diseased vessels, and the 
presence of heart failure during admission were 
the only independent predictors of long-term 
survival. Patients with an EF of 0.50 or greater 
Fig 3. Probability of l-year survival is calculated 
for patients with anterior and inferior MI in the ^̂  
Western Washington lntracoronary trial.” 
had a >95% probability of survival regardless of 
the extent of vessel disease. Patients with 
impaired ventricular function had a worse prog- 
nosis with worsening EF and with more extensive 
arteriographic vessel disease. Hugenholtz62 dem- 
onstrated that a curvilinear relationship exists 
between EF and survival probability. Patients 
with an EF >45% have a ~5% probability of 
death in the first year. Stadius et a163 showed that 
impairment of ventricular function appears espe- 
cially important in patients with anterior MI 
(Fig 3). The probability of l-year mortality 
becomes ~10% for patients with anterior MI 
when the EF value decreases below 45%. 
Patients with inferior Ml do not reach a 10% 
probability of death until the EF decreases below 
35%. 
The widespread availability of radionuclide 
EF determination has allowed large numbers of 
patients to be studied and stratified according to 
risk. The Myocardial Infarction Limitation 
Infarct Size (MILIS) study group64 and the 
Multicenter Post-Infarction research group6’ 
both found that radionuclide EF independently 
predicted survival in 533 and 781 patients fol- 
lowed in these two studies (Fig 4). Ahnve et a166 
followed 632 patients for at least 1 year. Patients 
with EFs >55% had a better than 90% survival 
probability. Survival probability worsened with 
worsening EF levels. In this study, an EF value of 
0.45 optimally segregated low- and high-risk 
subgroups. Poor EF and complex ventricular 
arhythmias additionally predicted an increased 
risk of cardiac death in all three studies. These 
natural history studies demonstrate the impor- 
tance of maintenance of ventricular function 
after acute MI in determining long-term surviv- 
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Fig 4. Probability of l-year mortality is related to 
radionuclide EF. A curvilinear response exists in the multi- 
center postinfarction research study.= 
al. To achieve a low risk for cardiac death, EF 
values >0.45 must be achieved. Patients with EF 
values 10.55 are at very low risk of cardiac 
death. These EF values should be remembered 
when assessing the clinical impact of reperfusion 
therapies. 
It is apparent that patients with ECG evidence 
of transmural injury presenting within 12 hours 
of symptom onset are a heterogeneous group with 
respect to coronary anatomy and ventricular 
function. The large majority of these patients 
present with involvement of the proximal or 
mid-LAD or RCA. Spontaneous recanalization 
and subtotal coronary occlusion occur in up to 
50% of the cases. A significant number of 
patients have well-developed coronary collaterals 
(most frequently in the RCA), Because of the 
presence of subtotal occlusion, spontaneous 
reperfusion, and collateral flow, improvement in 
ventricular function may occur naturally. The 
variable extent of collateral flow, occurrence of 
spontaneous reperfusion, and acute hemody- 
namic changes explain the great variability in 
ventricular function occurring within 24 hours of 
admission. Additionally, 30% of the patients may 
have spontaneous improvement during the hospi- 
tal stay and up to 50% improve in chronic 
follow-up. The least variability occurs in serial 
measures of global systolic function obtained at 
24 hours and predischarge. While spontaneous 
improvement in ventricular function is frequent, 
patients with persistent total occlusion and no 
collateral flow have a consistent and dramatic 
deterioration of global and regional function. 
Additionally, persistent severe coronary narrow- 
ing may prevent return of systolic function in 
reperfused, salvaged myocardial segments. Be- 
cause of the great heterogeneity, small trials 
must have treatment groups carefully character- 
ized by early and late angiography. Given the 
great variability of ventricular function occur- 
ring early after acute MI, the most sound analy- 
sis of ventricular function appears to be analysis 
of treatment effect on global or regional ventric- 
ular function in the convalescent phase. Because 
of the great spontaneous variability present in 
ventricular function, great caution and careful 
analysis of treatment groups must be used to 
assure that changes attributed to therapy would 
not have occurred by chance alone. 
MORTALITY DURING MYOCARDIAL 
INFARCTION 
Ultimately, the most important clinical ques- 
tion is not whether therapy can restore flow or 
improve function, but whether reperfusion ther- 
apy alters in-hospital and long-term survival. If 
survival is improved, then those reperfusion 
strategies that most effectively restore blood flow 
and improve ventricular function will be asso- 
ciated with the most effective improvement in 
survival. 
Since patients with transmural MI are so 
heterogeneous with regard to infarct size and 
location, incidence of complete coronary occlu- 
sion, incidence of spontaneous reperfusion, and 
other medical conditions, it is not surprising that 
heterogeneous prognostic groups exist (Fig 5). It 
is mandatory that careful analysis of inclusion 
and exclusion criteria for thrombolytic trials be 
examined to assure that comparable control 
groups are present. As Yusuf et a16’ demon- 
strated, mortality rates varying from 6% to 36% 
occurred in the early IV thrombolytic trials and 
vary from 6% to 38% in the randomized intracor- 
onary trials. Yusuf et al showed that if low-risk 
groups of patients are treated, enormous num- 
bers of patients must be enrolled to demonstrate 
a modest, positive treatment effect. 
In both design of future clinical investigation 
of reperfusion and in clinical patient care, it 
would therefore seem prudent to identify and 
treat patient subgroups of medium or high risk. 
A practical, useful method of identification of 
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% 
Fig 5. Control group mortality for the major pub- 
lished controlled IV and intracoronary streptokinase 
trials is presented. 54.36.38.76.126.141 WW,ST, western 
Washington Study; Dutch, Dutch Interuniversity 
Study: NYU, Mt. Sinai-New York University Study. 
medium or high risk patients in the emergency 
ward is necessary. Physical examination and 
admission ECG allow rapid, early segregation of 
risk groups. Patients with anterior MI location 
are known to be at higher risk (Table 1). Patients 
with inferior MI and reciprocal anterior ST 
changes are also at increased risk.68-7’ Previous 
natural history studies72T73 showed that a second 
MI involving a new myocardial distribution also 
adversely affects survival. Conversely, patients 
with isolated, first inferior MI have an excellent 
in-hospital and 1 -year survival. 
In addition to ECG MI location, physical 
examination allows segregation of low- and high- 
risk groups. Before the advent of thrombolytic or 
beta-adrenergic blockade therapy, Killip and 
Kimball demonstrated that risk groups with a 
hospital mortality of 6%, 17%, 38%, and 81% 
could be identified on the basis of admission 
physical examination.74 In patients who are 
eligible for reperfusion therapy, the Gruppo Ital- 
iano per lo Studio Streptochinasi nell’Infarcto 
Miocardio (GISSI) trial confirms the prognostic 
value of stratification according to Killip Classi- 
fication. 7s In this multicenter trial, mortality in 
Table 1. Risk Stratification for Acute Ml 
Mortality (%) 
Low risk 
First, inferior MI 
Killip class I 
Medium risk 
Anterior Ml 
Killip class II 
Inferior Ml with reciprocal ST change 
High risk 
Second Ml 
Age n-me than 75 years 
Killip class Ill 
Extreme risk 













the control group was 7.3%, 19.9%, 39.0%, and 
70.1% for Killip Classification I to IV, respec- 
tively. 
A third determinant of prognosis that is imme- 
diately available to clinicians is the patient’s age. 
With advanced age, mortality dramatically 
increases with conservative care. Unfortunately, 
the morbidity and mortality of invasive proce- 
dures,76 coronary bypass,77 emergency PTCA,78 
and thrombolytic therapy79 are also significantly 
higher. A major unanswered question is whether 
any reperfusion strategy will beneficially alter 
mortality in the aged. 
These three simple, quickly available clinical 
parameters allow rapid segregation of risk 
groups. The highest risk occurs for patients in 
cardiogenic shock or pulmonary edema. Medium 
risk is present for patients with anterior MI, 
inferoposterior or inferolateral MI, second MI, 
and in the elderly. Patients with a first inferior 
MI who have no signs of heart failure are at low 
risk. If reperfusion is applied to low-risk groups, 
other endpoints apart from mortality must be 
examined, since it is unlikely that a decrease in 
mortality will occur. 
THE THROMBOLYTIC AGENTS 
Because reperfusion therapy first used throm- 
bolytic agents, we will review the properties of 
the thrombolytic agents, with particular atten- 
tion to new-generation enzymes with heightened 
efficacy. Streptokinase became available in the 
late 1950~,~’ but its use in acute MI was limited 
until the 198Os, when there was adequate angio- 
graphic documentation of coronary occlusion 
and thrombolysis. More recently, new clot-sensi- 
tive agents that can achieve similar efficacy as 
intracoronary streptokinase but allow rapid, sim- 
ple, IV delivery became available (Fig 6). 
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Fig 6. The mechanism for clot-specific thrombolytic 
agents is schematized. While systemic thrombolytic agents 
activate circulating plasmin, clot-specific agents only acti- 
vate plasmin on the clot surface. SK: streptokinase. 
Streptokinase 
To date, the largest experience with any agent 
has been with streptokinase. In two recent Euro- 
pean randomized trials, over 7,000 patients were 
treated with 1.5 million units of streptokinase 
compared with placebo or conventional treat- 
ment.75~8’ In these large trials, angiography was 
not performed. In a pooled analysis of most of the 
smaller clinical trials of IV streptokinase with 
angiographic patency data, 50% efficacy was 
shown.82 Despite the very high dose of streptoki- 
nase used, this disappointing rate of infarct vessel 
recanalization may be attributed to the lack of 
clot-specificity of streptokinase. Streptokinase 
binds indiscriminately to circulating plasmin- 
ogen or clot-bound plasminogen. As a result, 
there is systemic activation of the hemostatic 
system components with consumption of plas- 
minogen, fibrinogenopenia, and high titers of 
fibrinogen degradation products (Fig 6). In most 
patients, this results in low levels of fibrinogen, 
usually ~50 mg/dL. However, in the majority of 
patients, the fibrinogenolysis is well tolerated, 
and significant bleeding episodes are uncommon. 
The frequency of serious bleeding episodes, 
including intracranial hemorrhage, in the large 
GISSI trial was 0.03%.” 
The systemic lytic effect of streptokinase may 
have other potential advantages or disadvan- 
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tages. Previous studies with intracoronary strep- 
tokinase demonstrated that a systemic lytic 
effect after streptokinase is required for maxi- 
mum patency to be achieved.83,84 After infarct 
vessel patency is established, the prolonged state 
of fibrinogen breakdown may promote sustained 
patency. However, this point remains theoretical 
because reocclusion appears to occur in the 12% 
to 25% of patients after reperfusion with strepto- 
kinase.x5-x7 In turn, high levels of fibrinogen 
degradation products (FDP), affect platelet 
function by inhibiting aggregation.” While this 
factor may also promote infarct vessel patency, 
the combination of critically low clotting proteins 
and platelet dysfunction may increase the hazard 
of bleeding after surgical procedures. In the 
setting of acute MI, patients may require coro- 
nary artery bypass surgery and the risk of signifi- 
cant bleeding after streptokinase may be appre- 
ciable.89 
Because streptokinase is derived from beta- 
hemolytic streptococci, the body recognizes this 
enzyme as a foreign protein. The incidence of 
allergic reactions is, however, relatively low, and 
~5% in most reported seriesg0s9’ consisting of 
fever, drug rash, and anaphylactoid reactions in 
decreasing order of frequency. Resistance is 
likely in patients treated with a second dose of 
streptokinase and may even be seen with primary 
treatment, particularly in patients with very high 
levels of antistreptococcal antibody (ASO) ti- 
ters. 
A major untoward side effect of high-dose IV 
streptokinase therapy is hypotension, which may 
be a significant problem in patients with baseline 
hemodynamic compromise. The incidence of 
hypotension ranges from 2% to 15% in reported 
series.90-92 Lew et al required the use of vasopres- 
sors, particularly norepinephrine, in nearly 15% 
of the patients92 treated with IV streptokinase. 
Overall, streptokinase is moderately effective 
but has no clot selectivity, and has the worse side 
effect profile among the agents available. Its 
cost, however, is the least, and is approximately 
$150 to $200 for 1.5 million units. 
Urokinase 
The naturally occurring enzyme urokinase has 
several advantages over streptokinase. However, 
its use has been limited by the cost of this agent, 
which is approximately $1,500 to $2,000 for 2 to 
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3 million units. Clinical trials with JV urokinase 
have shown that its efficacy may be better than 
streptokinase (60% to 65%), but the experience is 
limited and a randomized trial of streptokinase v 
urokinase has not yet been completed. A recent 
urokinase v tissue plasminogen activator trial 
demonstrated a high (>65%) patency for IV 
urokinase at a dose of 3 million units.93 
At equimolar doses of urokinase and streptoki- 
nase, slightly less systemic activation of fibrino- 
gen does occur. However, at the large doses of 2 
to 3 million units of urokinase currently used, 
severe fibrinogenopenia occurs with values of 
fibrinogen < 10% to 20% of baseline present after 
therapy.94 Compared with streptokinase, little or 
no hypotension, allergic reactions, primary or 
secondary resistance have been found after uro- 
kinase therapy. Urokinase can be administered 
as a bolus without an apparent change in efficacy 
or increased toxicity.93,94 Recently, in vivo syner- 
gism with tissue-type plasminogen activator and 
urokinase was suggested.95 This synergistic effect 
was not seen with urokinase and its parent mole- 
cule pro-urokinase.” 
Tissue Plasminogen Activator 
Tissue plasminogen activator (rt-PA) was first 
administered to a patient in 198 196; at that time, 
the material was derived from a melanoma cell 
line. With recombinant DNA techniques, the 
genetic expression and cloning of rt-PA became 
possible and the first patients were treated in 
early 1984.97 Since the initial use of rt-PA for 
acute MI, there were over 5,000 patients treated 
with two different preparations. The first form of 
t-PA that was available was a two-chain prepara- 
tion with a half-life of approximately four to five 
minutes.98 More recently, the predominant sin- 
gle-chain preparation was used and the half-life 
was reduced approximately 40%. Due to the 
difference in clearance, the effective doses for the 
two preparations varied, but their overall effi- 
cacy was similar-70% to 75%.98 Since the sin- 
gle-chain form will be commercially available, 
suggested doses will refer to this preparation. 
The IV dose of rt-PA that has proved effective 
ranges from 60 mg to 100 mg over the first hour. 
A total dose of 100 mg IV over three hours is now 
the FDA-approved dose. The work of Top01 et 
al99 suggests that a dose adjusted by weight may 
reduce fibrinogen breakdown and bleeding com- 
plications.99A dose of 1 mg/kg over the first 
hour, with 10% of this dose administered as a 
bolus was used in previous trials.“’ After the first 
hour, a prolonged low-dose maintenance of rt-PA 
(10 mg/hr to 20 mg/hr for four to eight hours) 
appears to reduce the incidence of reocclusion, 
lessens the residual stenosis as detected by quan- 
titative angiography, and is not associated with 
further hemostatic breakdown.“’ 
Several theoretical advantages are present for 
rt-PA therapy compared with streptokinase. 
First, as the physiologic mediator of fibrin disso- 
lution, rt-PA is an efficient enzyme that circu- 
lates naturally in very small quantities (2 ng/mL 
to 15 ng/mL). This enzyme requires the presence 
of the plasminogen-fibrin complex for avid bind- 
ing to occur, rendering t-PA clot selective. How- 
ever, if too much rt-PA is present, circulating 
plasmin may be formed and, in turn, break down 
fibrinogen. Thus, rt-PA offers relative clot 
selectivity, a predominantly dose-dependent phe- 
nomenon.88,89 Despite the use of low doses in 
patients, however, there may be significant 
depletion of fibrinogen that resembles the sys- 
temic lytic state associated with streptokinase 
and urokinase. The relative clot selectivity ac- 
counts for, in part, the heightened thrombolytic 
efficacy of rt-PA compared with streptokinase as 
determined in two randomized trials.‘02~‘03 
Second, owing to the enzyme’s short half-life, 
an infusion of rt-PA may be discontinued in the 
event of untoward bleeding. This might allow for 
more simple and rapid management of a bleeding 
complication, as compared with other thrombo- 
lytic agents (eg, streptokinase and urokinase) 
that have a long half-life. Third, like urokinase, 
rt-PA is a natural human enzyme, and no resis- 
tance or allergic phenomena have been observed. 
The bleeding complications that occur after 
rt-PA differ from those compared with streptoki- 
nase or urokinase. Chiefly, bleeding after rt-PA 
is usually due to fibrinolysis and is more likely to 
occur acutely. Bleeding at peri-access sites, gin- 
gival mucosa, or even gastrointestinal sites may 
occur soon (within one hour) after onset of 
therapy. On the other hand, bleeding after the 
nonselective agents is due to fibrinogenolysis and 
is slightly more apt to occur several hours or even 
days after therapy is initiated. It is very difficult 
to define accurately the risk of bleeding attribut- 
able to thrombolytic therapy alone, because 
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patients often receive concomittant anticoagula- 
tion and antiplatelet therapy. 
A rapid-acting, low molecular weight inhibitor 
to rt-PA is present in humans and at increased 
concentration in patients with coronary artery 
disease and hypertriglyceridemia.104”05 The exact 
physiologic role of the inhibitor is not known, but 
its activity is markedly reduced by activated 
protein C.lo4 
Recently, synergism of rt-PA with pro-uroki- 
nase and t-PA with urokinase was shown in the 
rabbit jugular vein mode19’ and in patients with 
acute coronary thrombolysis.106 This property 
may allow for small (eg 10 mg) quantities of each 
of two thrombolytic agents to be used with 
similar efficacy as expected with a single agent at 
high doses. Synergism may enable high clot 
selectivity, less material to be required in order to 
achieve thrombolysis, and perhaps increased effi- 
cacy. Now that rt-PA has been sequenced and 
cloned, there is potential for controlled changes 
in the molecule such that modified, hybrid rt-PA 
enzymes with different clot selectivity, half-life, 
and related properties can be produced. 
Pro-Urokinase 
Like rt-PA, pro-urokinase, ie, single-chain 
urokinase plasminogen activator (scu-PA), is a 
naturally occurring human enzyme that can be 
produced from renal-cell carcinoma cell culture 
or via genetic engineering techniques. Pro-uroki- 
nase is the precursor to urokinase, but unlike the 
latter, the single-chain form has fibrin selectivi- 
ty. Under conditions when no fibrin is present, 
there is circulating inhibitor to scu-PA. The 
properties of this inhibitor are not yet fully 
defined. When fibrin is present, the inhibitor is 
inactivated, thus rendering scu-PA clot selective. 
The relative extent of clot selectivity of scu-PA is 
similar to that of t-PA; at higher doses there is 
less fibrin specificity.“‘-” 
In addition to having allergic potential, (scu- 
PA) has a short half-life. Dosing appears to be 
very similar to rt-PA, as described above. 
Thrombolytic efficacy has been demonstrated to 
be in the 65% to 75% range, but larger, com- 
pleted studies are not available, and there is 
considerably less experience with this agent com- 
pared with rt-PA. The scu-PA enzyme has the 
potential to heighten clot-selective thrombolysis 
by virtue of its synergistic effect with rt-PA.95,106 
Acylated Streptokinase 
The acylated derivative of streptokinase (AP- 
SAC) has several properties that differ from the 
parent compound. This preparation can be given 
as a bolus over two to four minutes, and unlike 
streptokinase, it has a less significant hypoten- 
sive effect. APSAC has a long duration of action, 
and the allergic effects appear to be reduced 
compared with streptokinase.‘12-114 The thrombo- 
lytic efficacy of 30 mg of APSAC, the currently 
used dose, is quite similar to that of intracoro- 
nary streptokinase as demonstrated by a large, 
multicenter trial.‘15 As with streptokinase, there 
does not appear to be any clot selectivity asso- 
ciated with APSAC.‘16 This property may 
account for a decreased thrombolytic efficacy 
compared with that of rt-PA but as yet, no 
randomized study exists to compare these two 
new agents. 
Over the past few years, new clot-selective and 
derivative preparations have become available. 
Although the efficacy of these IV thrombolytic 
agents is greater compared with the first-genera- 
tion agents, there is likely to be further progress 
in the refinement of thrombolytic therapy. 
Synergism with clot-selective enzymes and new 
modifications of the rt-PA molecule provide 
exciting potential. 
CLINICAL TRIALS OF THROMBOLYTIC THERAPY 
Intracoronary Streptokinase Administration 
After Rentrops’ pioneering investigations,34 
numerous small, nonrandomized clinical trials of 
intracoronary streptokinase were conduc- 
ted.117F123 These studies were flawed in design but 
demonstrated that intracoronary streptokinase 
could be safely administered within the first six 
hours of acute MI. In 1985, Simoons et a135 
reported the last prospective randomized trial of 
intracoronary streptokinase infusion. In total, 
seven major prospective randomized clinical 
trials of intracoronary streptokinase administra- 
tion were published.34-40 
In the first angiographically controlled study, 
Khaja et al determined39 that intracoronary 
streptokinase infusion was significantly more 
effective than placebo in achieving coronary 
recanalization. Reported recanalization rates 
have varied for intracoronary infusion, and range 
from 60% to 90%.82 In review of the randomized 
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Fig 7. Efficacy of intracoronary streptokinase administration. Angiographically documented reperfusion rates for the 
randomized intrecoronary streptokinase trial are presented. Pooled reperfusion rate is similar to that for the Society of 
Cardiac Angiography study.“’ 
trials, it is apparent that efficacy is related to 
time of onset of infusion (Fig 7). In the two 
clinical trials in which therapy was initiated 
within four hours of symptom onset, reperfusion 
rates of 70% were achieved. Those studies with 
therapy initiated between four and 4.5 hours had 
the lowest recanalization rates. At this time, the 
fibrin clot presumably is more refractory to 
thrombolytic therapy. Later, some element of 
endogenous thrombolysis occurs and reperfusion 
rates again slightly improve. Overall, a reperfu- 
sion rate of 70% was achieved in pooling the 
results of the seven clinical trials. This reperfu- 
sion rate is comparable to that reported in the 
large registry of the Society of Cardiac Angi- 
ography.l17 
While intracoronary streptokinase conclu- 
sively reestablished antegrade blood flow, con- 
flicting results were found concerning changes in 
ventricular function after therapy. A time depen- 
dency for efficacy in improvement of global or 
regional left ventricular (LV) function occurs 
(Fig 8). As these randomized clinical trials dem- 
onstrate, patients treated conventionally have no 
change in serial global EF measured acutely and 
prior to hospital discharge. Two of seven studies 
found a significant increase in EF in streptoki- 
nase-treated patients. These studies had the 
highest reperfusion rates and shortest time to 
initiation of therapy. Patients treated after four 
hours of symptom onset had no change in global 
EF with therapy. The lack of improved global 
LV function does not preclude the possibility that 
survival may be improved with successful thera- 
py. Based on review of these randomized clinical 
trials, it is apparent that intracoronar~~ streptoki- 
nase will result in improved global LV function 
when treatment is initiated early after symptom 
onset. However, therapy initiated four or more 
hours after symptom onset is unlikely to result in 
improved global LV function. 
Eflect of Intracoronary Therapy on Mortality 
Finally, the most fundamental question must 
be addressed. Does intracoronary streptokinase 
result in improved survival? As Yusuf et al have 
demonstrated,67 each randomized intra~ronary 
streptokinase trial lacks sufficient power to dem- 
onstrate conclusively a survival advantage. 
When the intracoronary trials are pooled (Fig 9), 
a trend toward mortality reduction is apparent. 
Only two clinical trials, the Western Washington 
tria13’ and Netherlands Interuniversity triai3’ 
randomized over 100 patients in each treatment 
group (Table 2). In the Netherlands trial, l-year 
survival was 91% in the thrombolysis group (n = 
269) compared to 84% for the control (n = 264) 
P = .Ol. In the Western Washington trial, 
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Fig 8. Impact of intracoronary streptokinase on chronic global EF (randomized trials). impact of streptokinase therapy is 
related to time to onset of infusion.34JB”719”0~‘*4~“g Rentrop% did not report chronic EF for treatment groups. No changes in EF 
occurred for streptokinase-treated patients or placebo-treated patients. 
l-month mortality was reduced from 11.2% for 
116 control patients to 3.7% for 134 streptoki- 
nase-treated patients. The beneficial impact of 
streptokinase therapy was lost at l-year follow- 
up. One-year survival was 92% compared to 85% 
for streptokinase and control groups, respec- 
tively. Again, because of the relatively small 
sample size, a real mortality reduction at 1 year 
may have been missed. Apart from differences in 
sample size, a further major difference in ther- 
apy of patients after thrombolysis in these two 
trials merits observation. In the Western Wash- 
ington trial, 28% of the patients treated with 
thrombolytic therapy underwent revasculariza- 
tion with PTCA or bypass in the year after 
therapy. In the Netherlands trial, 46 patients in 
the thrombolysis group underwent immediate 
PTCA after successful thrombolysis and 62 
underwent elective PTCA or bypass after dis- 
charge. In total, 108 out of 269 (40%) of the 
patients in this trial underwent revascularization 
after thrombolytic therapy. The differences in 
revascularization may explain the differences in 
l-year mortality present in these two trials, since 
in the Western Washington trial, late mortality 
was highest in patients with anterior MI who had 
partial reperfusion. 
A second major difference in these trials was 
the time to initiation of therapy. The Western 
Washington trial was strictly an intracoronary 
infusion study with therapy started a mean of 4.3 
hours after symptom onset. In the Netherlands 
trial, intracoronary therapy was initiated 3.2 
hours after symptom onset in the first 152 
patients. In the last 117 patients, IV streptoki- 
nase was administered prior to catheterization. 
Overall, in the later trial the median time from 
symptom onset to hospital admission was 1.5 
hours. In spite of these differences in trial design, 
overall 30-day mortality was similar at 6.3% for 
the Netherlands trial and 7.2% for the Western 
Washington trial. Mortality in the control group 
was also similar at 12% and 11.2%, respectively. 
Thirty-day mortality was 3.7% in the Western 
Washington thrombolysis group and 5.9% in the 
Netherlands thrombolysis group. Despite the 
earlier time of presentation and significant 
improvement in global EF for the Netherlands 
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Fig 9. Odds ratio for mortality reduction is presented for the intracoronary streptokinase trials.” Values to the left of 1 .O 
represent a decreased mortality compared to control. The pooled results suggest e mortality reduction. because of the 
relatively small sample size, the 95% confidence interval crosses 1.0. The Netherlands study was not included in this 
analysis. 
trial, the 30-day mortality was similar for both 
studies. These findings suggest that myocardial 
reperfusion has a beneficial prognostic impact on 
30-day survival independent of improvement in 
global ventricular function or limitation of tomo- 
graphic thallium infarct size.‘24 Late survival 
may be contingent on completeness of revascu- 
larization after intracoronary streptokinase ther- 
w. 
In summary, intracoronary streptokinase 
results in reperfusion rates of approximately 
70%, with efficacy somewhat contingent upon 
the time of initiation of therapy. Global ventricu- 
lar function can be improved with very early 
therapy. A significant reduction in mortality 
occurs with therapy. This mortality reduction 
may be independent of the extent of myocardial 
salvage or improved global LV function. To 
enhance late survival, further revascularization 
may be required, especially in patients with 
anterior MI and partial reperfusion. 
IVStreptokinase Therapy 
From Fletcher’s first use of IV streptokinase 
therapy in 19591z5 to the European Cooperative 
Study Group trial in 19791z6 prolonged IV infu- 
sion of streptokinase was the standard method of 
administration. A great deal of the early contro- 
versy concerning the efficacy of IV streptokinase 
related to a lack of consensus concerning the role 
of thrombotic coronary occlusion and the effi- 
cacy of streptokinase in inducing coronary 
Table 2. Comparison of Western Washington and Netherlands Interuniversity Trials 
30.Day 1 -Year 
Reperfusion Early Late 
Mortality Mortality 
Symptom Rate PTCA PTCA 
(%) 1%) 
Trial M T  C Duration* 1%) 1%) (%) T  C T  C 
Netherlands 533 269 264 3.2 79 17 23 5.9 12 9 16 
Western Washington 250 134 116 4.0 68 28 3.7 11.2 8 15 
Abbreviations: M, mortality; T ,  thrombolysis group; C, control group. 












thrombolysis. The widespread use of early car- 
diac catheterization during acute MI allowed for 
documentation of the efficacy of IV streptoki- 
nase. Schroeder’s pioneering work demonstrated 
that 52% of the patients treated with a 30-minute 
infusion of 500,000 units of streptokinase had 
angiographically documented immediate coro- 
nary thrombolysis.‘27 A plethora of studies of 
reperfusion rates varying from 31%128 to 96%12’ 
have been reported. Rogers et a113’ demonstrated 
that a dose-response relation exists since only one 
of ten patients treated with 500,000 units had 
documented reperfusion, while seven of 16 
patients treated with l-million units did so 
(P < .005). Currently, most IV regimens consist 
of a l-million to I .5 million-unit infusion over 45 
minutes to one hour; higher doses are under 
investigation. 
In addition to a dose-response relationship, a 
clear temporal relationship for efficacy of reper- 
fusion is present (Fig 10). A major methodologic 
difference that obscured comparisons of reperfu- 
sion rates in many trials was the lack of system- 
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atic baseline angiography before the initiation of 
therapy. Proponents of baseline angiography 
favored documentation of coronary occlusion 
before the initiation of therapy.13’ Others felt 
that baseline angiography delayed the initiation 
of therapy and decreased its etIicacy.‘33 Compar- 
isons of trials with and without baseline angi- 
ography suggests that reperfusion rates were 
lower in patients in which posttreatment angio- 
grams were performed. After four hours of 
symptom onset, less than 50% of the vessels were 
recanalized. Up to 77% of vessels may be reca- 
nalized with therapy administered within three 
hours of symptom onset. Since very early initia- 
tion of therapy appears crucial, both for decreas- 
ing mortality75 and preservation of ventricular 
function,‘3p future trial designs should incorpo- 
rate early IV therapy followed by immediate 
posttreatment angiography to document reperfu- 
sion. With this trial design, a reperfusion rate 
approaching 60% for IV streptokinase therapy is 
expected, and other thrombolytic agents must be 
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Fig IO. Effect of symptom duration on efficacy of IV streptokinase. The angiographicaily documented reperfusion rates 
for the published IV trials using immediate angiography are presented.‘m~‘30’3’ 
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Fig 11. Impact of IV streptokinase on chronic global EF (randomized trials). Effect of IV streptokinase on chronic EF is 
compared to the time of onset of therapy.“‘Z4’4’-‘” 
STREPTOKINASE 
nized, however, that up to 20% of the patients 
treated will have subtotal coronary occlusion 
prior to therapy. The clinical impact of thrombo- 
lytic therapy in this subset of patients was not 
addressed. 
The published studies comparing IV to intra- 
coronary streptokinase administration have been 
reviewed by Lo.‘~’ The pooled reperfusion rates 
were 73% for IV and 72% for intracoronary 
therapy. Methodologic problems exist with all 
these studies except for that of Rogers et a1.13’ 
This study randomized 51 patients who had 
documented coronary occlusion to IV or intra- 
coronary therapy. Intracoronary therapy was 
significantly more effective than IV therapy. 
Patients were treated later than 5.5 hours after 
symptom onset in this trial. Review of angio- 
graphically documented reperfusion studies 
(Figs 6 and 9) suggests that within three hours of 
symptom onset, reperfusion rates are comparable 
(with intracoronary therapy slightly superior). 
After three hours, intracoronary therapy is 
clearly more effective in achieving arterial reca- 
nalization. 
Five prospective placebo-controlled random- 
ized trials analyzed the impact of IV streptoki- 
nase therapy on chronic global ventricular 
function (Fig 11). The largest of these trials, 
Intravenous Streptokinase in Acute Myocardial 
Infarction (ISAM) enrolled 1,741 patients pre- 
senting within six hours of acute MI.141 Fifty-five 
percent of the patients treated with streptokinase 
had therapy initiated within three hours of symp- 
tom onset. Patients treated within three hours 
had a significantly higher EF compared with the 
heparinized control groups. No difference 
between treated and control group was present 
for patients treated three to six hours after 
symptom onset. In a smaller placebo-controlled 
trial, Schreiber et al studied 38 patients who 
were randomized within 3.3 hours of symptom 
onset.44 Serial radionuclide ventriculography 
demonstrated improvement only in the streptoki- 
nase-treated patients. Olson et a1’42 treated 52 
patients with streptokinase or placebo at 4.9 
hours after symptom onset. No change in global 
EF measured seven to ten days later occurred in 
either group. Recently, two other large, random- 
ized, placebo-controlled trials of IV streptoki- 
nase have been reported. The New Zealand 
study143 found improved global EF (53 f 13.5 v 
59 * 10.5% P c ,005) for patients with their first 
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infarct who were treated with streptakinas~. The 
Western Washington Intravenous tria1144 re- 
parted that the radionuclide EF is significantly 
higher (50.8 v 46.6, P < 0.02) for patients 
treated with streptakinase compared to placebo. 
Patients were treated 3.5 rt 1.4 hours from 
symptom onset in this 367-patient muiticenter 
study. 
Analysis of these randomized studies confirms 
that a time dependency for improvement in ven- 
tricular function exists (Fig 1 I>. Patients treated 
within four hours of symptom onset are likely to 
improve global LV function compared with pla- 
cebo. Of interest, enzymatic estimates of reper- 
fusion (early peak CK-MB) were 74%, 79%, and 
44% for the Schroeder, Schreiber, and Olson 
studies, respectively. The Schreiber and Olson 
studies were too small to anafyze the effect of 
therapy in the subgroups with anterior or inferior 
MI. The ISAM trial and the New Zealand study 
have subdivided patients based on MI location 
and found improvement in global ventricuiar 
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function for both anterior and inferior MI 
groups. The Western Washington trial also ana- 
lyzed patient subgroups and found that patients 
with anterior MI and those treated within three 
hours of symptom onset are most likely to 
improve global ventricular function. 
In summary, extensive data demonstrate that 
a time dependency is present both for coronary 
recanalization and improved global ventricular 
function with IV streptokinase therapy. Patients 
treated within three hours of symptom onset are 
most likely to have coronary recanalizatian and 
improved ventricular function. Further studies 
are required to more extensively analyze changes 
in regional wall motion, ventricular response to 
exercise, and to identify subgroups most likely to 
benefit from therapy. 
&feet of IV Therapy on Mortality 
IV streptokinase trials attempting to demon- 
strate improved survival have been conducted 
since the mid 1960s. To date, over 20,000 
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Fig 12. The odds ratio of the pooled controlled trials of streptokinase is present. BI The 95% confidence interval remains to 
the left of 1. suggesting an unequivocal mortality reduction. The GlSSl Study, ISAM Study, and ISIS il trial were not completed 
at the time of this analysis. 
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patients have been enrolled in published placebo 
controlled trials. Because of this voluminous 
experience, definitive conclusions regarding effi- 
cacy of therapy can now be made. Yusuf et a167 
has pooled all prolonged infusion trials and dem- 
onstrated that a 22% risk reduction occurs with 
streptokinase therapy (Fig 12). Because of the 
large number of patients treated, this mortality 
reduction achieved great statistical power. Of 
interest, in Yusuf’s analysis a time dependency 
for mortality reduction did not seem to exist. In 
the largest, most recent prolonged infusion trial 
(The European Cooperative Study), mortality 
was reduced from 30.6% to 15.6% (P < .Ol) at 
six months.‘26 This mortality reduction occurred 
although streptokinase infusion began a mean of 
eight hours after symptom onset. While the exact 
mechanism for mortality reduction in these early 
trials in unknown, it is unlikely that a beneficial 
reduction of MI size occurred. Mortality reduc- 
tion may be related to delayed reperfusion in 
these trials. Since brief, high-dose infusion proto- 
cols are most frequently used now, the findings 
from earlier studies may not be applicable. 
Table 4. GISSI Study Subgroup Analysis 
Decreased Mortality 
Anterior Ml, multiple location MI 
First Ml 
Age <65 
Symptoms ~6 hours 
Men and women 
Killip class I and class I/ 




Symptoms >6 hours 
Killip class Ill and class 
IV 
Fortunately, two large, randomized, brief, 
high-dose IV trials have been reported. The 
multicenter GISSI tria175 randomized 11,806 
patients and found a significant reduction in 
mortality for patients treated within six hours of 
symptom onset. The German multicenter ISAM 
trialr4’ randomized 1,746 patients and found no 
reduction in mortality. The similarities and dif- 
ferences in these studies must be examined to 
draw conclusions concerning brief, high-dose IV 
therapy (Table 3). 
up to 12 hours from symptom onset while the 
ISAM trial only enrolled patients up to six hours 
from symptom onset. Second, the control group 
mortality was almost doubled in the GISSI trial 
(13% v 7.1%). Since control group mortality was 
identical for anterior and inferior MIS in these 
studies, the preponderance of inferior MIS 
enrolled in the ISAM trial may have diluted the 
potential benefit of thrombolytic therapy. Final- 
ly, the control patients in the ISAM trial were 
heparinized while the GISSI control patients 
were not. Since heparin therapy alone can induce 
reperfusion chronically in up to 50% of the 
infarct arteries, this drug may alter mortality 
itself. An unexplicable finding is the apparently 
higher mortality for streptokinase treated 
patients with anterior MI in the ISAM trial 
(20% v 17% for control). Since 80% of all GISSI 
coronary care units (CCUs) participated in the 
GISSI trial, it is likely that this study was more 
representative of all patients presenting during 
the early phase of acute MI. Because of the low 
control-group mortality in the ISAM trial, no 
survival advantage could be demonstrated. 
When comparing these two studies, three 
major differences apart from sample size are 
apparent. First, the GISSI trial enrolled patients 
The large number of patients treated in the 
GISSI trial allows for analysis of subgroups of 
patients, Table 4. The most striking mortality 
reduction occurred in patients treated within one 
Table 3. Randomized High-Dose IV Streptokinase Trials 
Symptom 
Mortality (96) Anterior (%) inferiw (%I 
Study No. of Patients Duration (h) T  c T  c T  c 
GISSI’” 11,806 12 10.7 13.01 14.5.f 18.4 6.8 7.2 
lSAM’4’ 1,743 8 6.3 7.1 20.1 17.4 4.0 4.6 
New Zealand’” 219 4 3.7 12.5 - - 
ISIS IIS’ 4,000 4 8 ‘3 - - - 
Western Washington’44 367 6 6.3 9.6 10.4 22.45 4.0 1.8 
Abbreviations: T, treated patients; C, controls. 
*P < .ooo!i. 
tP< .OOl. 
SReported as “proof beyond reasonable doubt.” 
§P .05. 
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hour of symptom onset. In this subgroup, a 47% 
mortality reduction occurred (15.4% to 8.2%, 
P = .OOOl). Mortality reduction occurred for 
both males and females. Only patients under age 
65 benefited from therapy. Patients with inferior 
or lateral MI had no mortality reduction, while 
those with anterior or multiple location MI did. 
Patients with first MI had mortality reduced 
while those with previous MI did not. Finally, 
patients with Killip Class I or II had reduced 
mortality while those with Class III or IV did 
not. In the GISSI trial, patients most likely to 
benefit from IV therapy were those age 65 or 
less, with anterior MI, without signs of heart 
failure who present within six hours of symptom 
onset of their first infarction. 
A third final, major IV trial is currently being 
conducted. The ISIS-II trial is designed to enroll 
20,000 patients in groups treated zero to four 
hours, four to 12 hours, and 12 to 24 hours after 
symptom onset. The policy board has reported 
that a significant mortality reduction already is 
present in patients treated zero to four hours.” A 
33% mortality reduction from 12% to 8% was 
achieved in this subgroup. Surprisingly, despite 
this mortality reduction, the investigators plan to 
continue to enroll patients until the 20,000- 
patient sample size is achieved. 
In summary, brief, high-dose IV streptokinase 
therapy is clearly beneficial when therapy is 
initiated early. An ~~eq~iv~caZ mortality reduc- 
tion is achieved with therapy initiated within six 
hours of symptom onset. Coronary reperfusion is 
most likely with therapy initiated within three 
hours of symptom onset. Improved ventricular 
function is also more likely to occur with therapy 
initiated within three hours of symptom onset. 
These studies demonstrate the urgent time 
dependency for clinical efficacy. Future trials 
must employ strategies in which therapy is insti- 
tuted as soon as possible including home or 
ambulance institution of infusion. The prolonged 
infusion trials suggest that mortality may be 
reduced independent of myocardial salvage. 
Future studies must determine whether delayed 
reperfusion independently imparts a survival 
advantage. 
CLINICAL TRIALS OF RECOMBINANT TISSUE 
PLASMINOGEN ACTIVATOR 
Van de Werf et al’& first reported that puri- 
fied re~mbinant tissue plasminogen activator 
(rt-PA) obtained from the Bowes melanoma line 
recanalized six of seven patients with total coro- 
nary occlusion. Two randomized, placebo-con- 
trolled, angiographic studies studied the efficacy 
of double-chain rt-PA in achieving arterial reca- 
nalization. Colleen et a19’ first demonstrated that 
rt-PA recanalized 75% of the patients with 
occluded coronary arteries in a 50-patient, multi- 
center study. Patients were treated with a one- 
hour IV infusion of 0.5 mg/kg rt-PA. Pretreat- 
ment angiography was required in this trial. For 
this reason, therapy was instituted at 4 t 1 hours 
after symptom onset. 
Verstraete et a114’ also studied the efficacy of 
rt-PA in achieving coronary recanalization com- 
pared to placebo control. Patients were randomly 
treated with IV heparin and a 0.75 mg/kg infu- 
sion of rt-PA or heparin plus placebo control. In 
this study, baseline, pretreatment angiography 
was not performed. Most patients were treated 
within four hours of symptom onset. Coronary 
recanalization was achieved in 61% of rt-PA 
treated patients compared to 21% of placebo 
control ( P < .OOl). A fall in fibrinogen level to 
52% rf: 29% of pretreatment value occurred in 
patients treated with rt-PA. No major bleeding 
complications occurred in this study. Only one 
patient required a blood transfusion. These stud- 
ies thus conclusively demonstrated the efficacy 
of IV rt-PA as a thrombolytic agent. 
As discussed earlier, the major advantage of 
rt-PA over previously available nonselective 
agents is the increased efficacy in achieving 
coronary recanalization. Two large published 
studies have addressed this issue. The National 
Heart Lung and Blood Institute (NHLBI) spon- 
sored Thrombolysis in Myocardial Infarction 
(TlMI) trial prospectively compared IV rt-PA 
with IV streptokinase.‘38a’46 In this study, 47 
patients were initially treated with a 90-minute 
infusion of double-chain rt-PA after baseline 
angiography. Coronary recanalization occurred 
in 25 of 37 (68%) of the patients with initial 
complete coronary occlusion. One third of the 
patients with reperfusion achieved by rt-PA 
reoccluded before hospital discharge. The TIM1 
study group subsequently performed a random- 
ized clinical trial in patients presenting within 
seven hours of symptom onset.“’ Patients were 
treated with I .5 million units of IV streptokinase 
or a three-hour rt-PA infusion. Therapy was 
initiated a mean of 4.6 hours after symptom 
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onset. Reperfusion was achieved in 60% of the 
rt-PA-treated patients compared to 40% of the 
streptokinase-treated patients ( P -c .OOl). 
Although initial reperfusion rates were higher 
for rt-PA, at hospital discharge an equal percent- 
age of patients had patent infarct arteries.14’ 
Coronary arteriography was repeated in 109 of 
143 rt-PA patients and 9X of 147 streptokinase 
patients. TIM1 Grade II or III flow was preSent 
in 79 of 109 rt-PA patients (72%) compared with 
72 of 98 streptokinase-treated patients (73%) 
P=NS. 
The European Cooperative Study Group”’ 
also studied the comparative efficacy of rt-PA 
and streptokinase. Patients were treated with 
0.75 mg/kg rt-PA over 90 minutes or 1.5 million 
units of streptokinase over one hour. At initial 
angiography (posttreatment), 70% of the rt-PA- 
treated patients had patent vessels compared to 
55% of the patients treated with streptokinase 
(P = .054). Fibrinogen levels were markedly 
lower for patients treated with streptokinase, and 
fibrin degradation products were significantly 
higher. 
With advances in recombinant DNA technol- 
ogy, a new predominantly single-chain rt-PA 







be available for widespread clinical application. 
In a placebo-controlled trial, Top01 et al have 
studied the thrombolytic efficacy of single-chain 
t-PA.” One hundred patients were treated with a 
three-hour infusion of rt-PA or placebo in a 
blinded random fashion. Angiography per- 
formed at 60 minutes demonstrated that 57% of 
the rt-PA-treated patients had patent arteries 
compared to 13% of the placebo-control patients 
(P < .OOl). At this point, therapy was unblinded. 
Drug infusion continued and angiography per- 
formed at 90 and 120 minutes demonstrated 
further increased coronary reperfusion with 69%, 
then 79% of the infarct arteries achieving angio- 
graphic patency with t-PA therapy. 
These reperfusion rates are higher than those 
achieved by IV streptokinase in the studies in 
which the two agents were compared.‘02*‘03 
Importantly, the time dependency present for 
efficacy of IV streptokinase therapy does not 
appear to exist for rt-PA (Fig 13). Although 
early coronary reperfusion is higher, final arte- 
rial patency may not be different. Ganz et a1’29 
have reported that 63 of 66 patients (95%) of the 
patients treated with high-dose IV streptokinase 
had patent infarct arteries when delayed cathe- 
terization was performed before hospital dis- 
160 240 300 
Symptom Duration Prtor to 
Onset of Infusion 
(minutes) 
prior to therapy 
Fig 13. Efficacy of IV tPA therapy. Reperfusion rates for the angiographicaIly documented rt-PA trials are compared to the 
time at which treatment was initiated.98.‘00.‘0’~,‘~ 
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charge. Since all other studies using early angio- 
graphy found much lower reperfusion rates with 
streptokinase, one could postulate that signifi- 
cantly delayed reperfusion occurred in the Ganz 
et al study. Current treatment regimens employ- 
ing rt-PA include a prolonged infusion of this 
agent. Delayed reperfusion may also occur with 
rt-PA therapy. In the run-in phase of the TIM1 
II Study,14’ 196 patients underwent catheteriza- 
tion 32 hours after the start of rt-PA infusion. 
TIM1 grade II or III perfusion was present in 
87% of the patients. Whether delayed reperfu- 
sion is of clinical benefit has not been deter- 
mined. Since myocardial salvage has been shown 
to be critically time dependent, reperfusion strat- 
egies yielding the highest, earliest levels of reper- 
fusion have greatest efficacy in salvaging myo- 
cardium. 
The impact of IV rt-PA therapy on ventricular 
function has not yet been subjected to extensive 
analysis. Top01 et al first examined the impact of 
rt-PA therapy on regional wall motion in a 
blinded, semiqualitative study of serial echocar- 
diography.i4’ Echocardiography was performed 
before rt-PA therapy, at 24 hours and 10 days 
after therapy. A marked improvement in 
regional wall motion occurred for patients 
treated with sequential rt-PA and PTCA, but no 
change occurred for myocardial segments reper- 
fused by rt-PA alone or those segments not 
reperfused. 
The effect of IV rt-PA therapy alone on ven- 
tricular function was addressed by the NHLBI- 
sponsored TIM1 Study reported by Sheehan et 
aI”’ and the multicenter Thrombolysis Angio- 
plasty Myocardial Infarction TAM1 Study 
reported in preliminary fashion by O’Neill et 
a1.15i During the TIM1 Study 290 patients were 
randomized to IV rt-PA or IV streptokinase 
therapy. Serial contrast ventriculograms were 
analyzed in 145 patients (77 rt-PA and 68 strep- 
tokinase treated). No serial improvement in 
global EF occurred for either subgroup. Final EF 
was 49.9% k 9.4% and 49.1% * 11.7%, P = .8.5 
for rt-PA and streptokinase patients, respec- 
tively. Regional wall motion significantly 
improved for both subgroups. Regional wall 
motion was identical predischarge 
(-2.6% -c 1.0% v 2.6% rt l.O%, P = .99). Thus, 
despite the higher early recanalization rates 
achieved by rt-PA, equivalent improvement in 
ventricular function occurred for both agents. 
Subgroup analysis revealed that significant 
improvement in global EF occurred for patients 
with subtotal coronary occlusion at the time of 
initial angiography and those with persistently 
patent vessels at the time of repeat catheteriza- 
tion. These authors further describe an interest- 
ing subgroup of patients who achieved delayed 
reperfusion. In 29 patients, angiography at the 
termination of thrombolytic therapy demon- 
strated an occluded vessel, whereas angiography 
at repeat catheterization found recanalization 
had occurred. No change in EF or regional wall 
motion occurred. 
In the TAM1 Study, 386 patients were treated 
with IV rt-PA.“’ Serial contrast ventriculogra- 
phy was performed in 266 of 359 surviving 
patients. Detailed linear regression analysis was 
performed to determine factors associated with 
improved global or regional wall motion.‘51 As 
reported by Top01 et al,100 a significant improve- 
ment in regional wall motion occurred for suc- 
cessfully reperfused patients who were candi- 
dates for immediate PTCA. No change in serial 
EF occurred. Ventricular function was signifi- 
cantly better at the time of hospital discharge if 
thrombolytic therapy was initially successful. 
Interestingly, in this study only those patients 
undergoing emergency coronary bypass surgery 
had improvement in global EF. 
Despite the earlier time to initiation of therapy 
in the TAMI Study (2.9 hours) v 4.9 hours in the 
TIM1 Study and the frequent use of immediate 
PTCA in the TAM1 Study, no differences in 
serial EF occurred. Significant improvement in 
regional wall motion occurred from both studies. 
Since neither study had a placebo control, the 
true impact of rt-PA on ventricular function is 
difficult to assess. 
The final major clinical question of whether 
rt-PA therapy reduces mortality remains unan- 
swered. The NHLBI sponsored TIM1 Study was 
initially designed to determine whether IV 
thrombolytic therapy improves survival. With 
publication of the GISSI Study the TIM1 inves- 
tigators felt it was not ethical to withhold throm- 
bolytic therapy. The TAM1 investigators concur- 
red with this decision. For this reason, no large 
placebo-controlled trials with mortality reduc- 
tion as a primary endpoint have been conducted 
with rt-PA. Since streptokinase and rt-PA are 
entirely different agents with differing hemody- 
namic effects, differing antiplatelet effects, and 
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differing biologic haIf-lives, extrapolating the 
mortality results from streptokinase therapy to 
rt-PA therapy may not be appropriate. In the 
future, the comparative efficacy of rt-PA and 
streptokinase on mortality reduction will be 
tested in the ISIS-III trial. 
In summary, rt-PA is an extremely promising 
thrombolytic agent. Its major advantage over 
nonselective agents is its enhanced thrombolytic 
efficacy. The efficacy of rt-PA compares favor- 
ably to intracoronary streptokinase and is more 
effective than IV streptokinase. The time depen- 
dency for efficacy is less striking for rt-PA than 
for streptokinase. Initial studies demonstrated 
that a major risk of reocclusion (up to 30%) 
existed after rt-PA-induced reperfusion. The 
prolonged infusion protocols currently used have 
decreased reocclusion rates to less than 15%. 
Although immediate reperfusion rates are higher 
with rt-PA than with streptokinase, final arterial 
patency may not be different. Therapy initiated 
within three hours of symptom onset will result in 
improved regional wall motion. No studies have 
shown improved global ventricular function with 
rt-PA alone. The impact of this therapy on 
mortality has not been addressed. 
CORONARY ANGIOPLASTY THERAPY OF 
MYOCARDIAL INFARCTION 
Mechanical coronary artery recanalization 
has been attempted since the earliest experience 
with cardiac catheterization during MI. Oliva 
first demonstrated that coronary recanalization 
could be achieved with contrast injections and 
intracoronary nitroglycerin.” Rentrop’s first 
experience with guidewire coronary recanaliza- 
tion was so impressive that he was stimulated to 
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pursue this therapy during acute MI?’ Early 
studies”’ suggested that higher rates of coronary 
recanalization could be achieved by subselective 
streptokinase administration. It is possible that 
some element of mechanical recanalization 
explained these early positive results. With the 
advent of balloon angioplasty technology,152 only 
a short period elapsed before PTCA was 
attempted during acute MI. Since initial cathe- 
ters and balloon tips were inflexible and rigid, the 
initial use of angioplasty occurred in patients 
with subtotal coronary occlusion after streptoki- 
nase therapy. 153~154 Hartzler et alIs5 and Meyer et 
a1’56 demonstrated that angioplasty could be 
safely and effectively performed after streptoki- 
nase in the first two large, published clinical 
series. 
The use of angioplasty in acute MI initially 
occurred to correct two major deficiencies in 
intracoronary streptokinase therapy. These defi- 
ciencies were the prevalence of severe residual 
stenosis after therapy and the lack of improved 
ventricular function with reperfusion. Subse- 
quently, a number of investigators have studied 
the efficacy of angioplasty alone in achieving 
arterial recanalization’57-‘6’ (Fig 14). Because of 
the inherent time delay involved in patient trans- 
port and angiography, most patients were previ- 
ously treated after three hours of symptom onset. 
Despite the delayed time to initiation of therapy, 
angioplasty consistently resulted in arterial 
patency rates above 80%. Thus, this therapy is 
superior to IV thrombolytic therapy in achieving 
arterial recanalization. Efficacy of therapy does 
not appear to be time dependent. 
The impact of angioplasty on improvement in 
ventricular function has not been adequately 
Fig 14. Arterial patency after primary 
angioplesty therapy. Reperfusion rates 
for primary PTCA therapy are compared 
to the time at which PTCA was performed 
after symptom onset.‘67-rs’ 
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addressed. CYNeill et al”* found that angioplasty 
resulted in a 7% increase in global EF while 
patients treated with intracoronary streptokinase 
alone had no serial change in global EF. Similar- 
ly, Rothbaum et al”’ prospectively treated 15 1 
patients with PTCA as the sole reperfusion 
agent. Patients were treated a mean of three -t- 
one hours from symptom onset. A striking 
increase in EF occurred in this uncontrolled 
study. Patients with anterior MI had an EF 
increase of 13% + 12% (P < .OO 1) and those with 
inferior MI increased 10% 2 12% (P < .OOl). 
Similarly, Hartzler reported a 16% increase in 
global EF for 27 patients treated 3.3 hours from 
symptom onset.ls5 Again, this study was uncon- 
trolled. Although all these studies lack true con- 
trol groups, the striking changes in global EF 
that occurred in the OWeill, Hartzler, and Roth- 
baum studies are impressive when compared to 
the results reported for ~hrombolyti~ therapy, 
Because of the enormous manpower and labo- 
ratory requirements, it is unlikely that a random- 
ized study of sufficient sample size will ever test 
the value of PTCA therapy alone in improving 
survival. Future clinical trials will most likely 
address the issue of the role of PTCA in improv- 
ing survival after thrombolytic therapy. Al- 
though it is unlikely that PTCA will be found to 
improve survival for all MI patients, certain 
high-risk subgroups may benefit. Patients with 
cardiogenic shock complicating acute MI are an 
extraordinarily high-risk subgroup. This group 
represents 12% of all patients with acute MI. A 
hospital mortality of 85% exists?’ with current 
therapy. Lee et al reviewed the University of 
Michigan experience with cardiogenic shock.‘62 
In this study, 83 patients with rigidly defined 
criteria for cardiogenic shock were treated 
between 1975 and 1985. A reduction in mortality 
from 83% to 50% occurred for the 24 patients 
treated with PTCA therapy compared to the 
conventionally treated patients. Other small clin- 
ica1 series have examined the impact of PTCA on 
mortality.*~~-i6~ OveralI, for the 74 reported 
cases, a 49% survival occurred. Since other ther- 
apeutic strategies including intraaortic balloon 
counterpulsation, coronary bypass,t6’ and 
thrombolytic therapy75 have not altered survival, 
PTCA is an extremely promising therapy for this 
high-risk subgroup. 
Another major subgroup that may benefit 
from PTCA includes those patients failing 
thrombolytic therapy. In a preliminary report, 
Califf et a116’ demonstrated the clinical utility of 
angioplasty after failed thrombolytic therapy. 
The TAMI Study treated 386 patients with 
transmural MI with IV rt-PA. Patients under- 
went catheterization within 90 minutes of onset 
of infusion. At angio~rap~y, 96 of 386 patients 
(25%) had faifed thrombolyti~ therapy. Ten of 
these patients had sm.afl infarcts and were 
treated conservatively; all did well. Angioplasty 
was attempted by 86 patients and resulted in 
reperfusion in 89% of the pat,ients, with a mortal- 
ity rate of 8%. Mortality for the 9 patients who 
failed both thrombolytic therapy and angioplasty 
was 44%. Although uncontrolled, these findings 
suggest that prognosis can be improved by angio- 
plasty-induced reperfusion after failed thrombo- 
lytic therapy. 
In summary~ the role of PTCA as primary 
therapy of acute MI has not been adequately 
defined. Early studies suggest that PTCA is 
superior to IV thrombolytic therapy and at least 
equivalent to intracoronary therapy15* in achiev- 
ing coronary recanalization. The O’Neill et al”’ 
and Erbel et a15’ studies suggest that PTCA is 
superior to intracoronary streptokinase in 
improving ventricular function. These findings 
must be corroborated by future studies. Angio- 
plasty has not been shown to improve survival 
except in patients with cardiogenic shock. 
Because of logistic and manpower constraints, it 
is unlikely that this therapy will be widely 
applied as a sole reperfusion treatment modality. 
The question as to whether a patient who is seen 
in a center with the capability of PTCA (within 
three hours of symptom onset) would best be 
treated by IV thrombolytic therapy alone or 
PTCA alone must await further study. 
Meyer et a1’53 first described the use of PTCA 
in MI in a 72-year-old female who developed 
cardiogenic shock 31 hours after successful 
intracoronary streptokinase therapy of a right 
coronary artery occlusion, PTCA of a subtotal 
RCA occlusion successfully reversed the shock 
syndrome. Other brief case reports soon 
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followed.i6g~‘70 These early studies all used PTCA 
after streptokinase therapy. 
Meyer et al first reported a large clinical series 
using PTCA after streptokinase therapy.lT6 In 
this study 64 patients were treated with intracor- 
onary streptokinase infusion. After angiography, 
21 patients were deemed suitable for PTCA; it 
was successful in 17 of 21 patients. Patients were 
selected based on the presence of high-grade 
residual stenosis. Patients failing thromboiytic 
therapy were not treated. Hartzler subsequently 
extended the use of PTCA to patients failing 
thrombolytic therapy.“’ The combination of 
thrombolytic agents and PTCA has provided 
high rates of coronary recanalization. Kitazume 
et al”’ achieved recanalization in 90% (20 of 22) 
of patients combining intracoronary urokinase 
and PTCA. Prida et al16’ successfully recana- 
lized 18 of 22 (82%) of the patients treated with 
streptokinasc and PTCA. Holmes et al also 
achieved successful recanalization in 23 of 29 
(79%) of the patients treated with streptokinase 
and PTCA.17z These early reports were retro- 
spective reviews of a clinical experience. Fung et 
al’34 first prospectively evaluated sequential IV 
streptokinase followed by immediate PTCA. 
Thirty-four consecutive patients were treated 
with 1.5 million units of IV streptokinase 2.6 
hours after symptom onset. Cardiac catheteriza- 
tion was immediately performed and PTCA was 
attempted on all suitable patients. PTCA was 
attempted on all 13 patients who failed lytic 
therapy with 12 of 13 having successful recanali- 
zation. PTCA was attempted in 16 of 18 patients 
with post-streptokinase therapy high-grade ob- 
structive lesions, and was successful in all 16. 
Three patients had less than 50% residual steno- 
sis at initial angiography. On discharge from the 
laboratory, this approach resulted in a recanali- 
zation rate of 97%. 
Combination therapy with PTCA and tissue 
plasminogen activator is now the focus of intense 
clinical investigation. Top01 et al’73 reported a 
pilot experience with PTCA and rt-PA. In this 
study, 38 patients were treated with a three-hour 
infusion of rt-PA. Catheterization revealed re- 
canalization in 32 of 38 (84%) of patients two 
hours after the onset of rt-PA infusion. PTCA 
was attempted in all six rt-PA failures with 
successful reperfusion occurring in five of six 
patients. Thus, 37 of 38 patients (97%) left the 
catheterization laboratory with patent coronary 
arteries. Based on this promising early experi- 
ence with combination rt-PA and PTCA, the 
multicenter TAM1 Study prospectively treated 
386 patients with IV rt-PA. PTCA was used in 
patients failing lytic therapy or those randomized 
to PTCA after successful thrombolysis (Fig 15). 
Angiography at 90 minutes demonstrated re- 
canalization in 288 (75%) of the patients. PTCA 
was performed in 86 of 96 patients with failed 
thrombolysis and was successful in 79 of 86 
(92%) of the patients. Thus, 358 of 384 (93%) of 
the patients were discharged from the laboratory 
with patent vessels. However, this study has 
pointed out the risk of immediate PTCA since 
7% of the patients undergoing PTCA after suc- 
cessful rt-PA therapy required urgent bypass due 
to coronary dissection or rethrombosis. 
A major deficiency of the combination of 
rt-PA and PTCA is the inability of this combina- 
tion to prevent coronary reocclusion. Gold et a1i6’ 
first suggested that PTCA could decrease reoc- 
elusion after streptokinase therapy. One of the 
major aims of the TAM1 Study was to prospec- 
tively test the value of immediate v elective 
PTCA in preventing coronary reocclusion after 
rt-PA therapy. Reocclusion occurred in 11% of 
the 99 patients treated with immediate PTCA 
and 13% of the patients with elective PTCA. 
Thus, after successful rt-PA therapy (&hour 
n 396 Enrotled 
d 99 Immediate PTCA 
( 4 0% morlality ) ( 1 0% mortahty ) 
Fig. 15. TAMI trial design. Patient triage for the TAMI 
Study is presented. At go-minute angiography. 75% of the 
patients had patent vessels. After “salvage PTCA,” 94% of 
the patients had patent vessels. Two patients did not 
undergo initial angiography.’ 
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infusion) no decrease in reocclusion occurred 
with immediate PTCA. The reocclusion rates 
after “salvage” PTCA in patients failing throm- 
bolytic therapy were even more disappointing. In 
the TAMI Study, 96 patients failed thrombolytic 
therapy. PTCA was attempted in 86 patients and 
successful in 79. At recatheterization 1 week 
later 29% of this subgroup had coronary reocclu- 
sion. 
The TAMI study group completed a pilot 
study of the combination of rt-PA and uroki- 
nase.‘74 This study was conducted to determine 
whether these agents had synergistic effects and 
whether coronary reocclusion could be lessened 
by a systemic fibrinolytic state. One hundred and 
forty six patients were treated with increasing 
doses of both agents. Recanalization rates were 
docunlented with immediate angiography. 
Group 1 received 25 mg &-PA and .5 megaunits 
urokinase. Group II received 25 mg rt-PA and 2 
megaunit urokinase. Group III received 1 mg/kg 
t-PA and .5 megaunit urokinase. Group IV 
received 1 mg/kg of rt-PA and 1 megaunit of 
urokinase. Group V received 1 mg/kg t-PA and 2 
megaunits of urokinase. Recanalization rates of 
36%, 37%, 71%, 72%, and 75% were achieved. 
These recanalization rates are no higher than 
those achieved by rt-PA above. Significantly, 
however, reocclusion rates were only 4%. 
IMPACT OF COMBINATION STRATEGIES ON 
VENTRICULAR FUNCTION 
Fung et al evaluated the impact of streptoki- 
nase and PTCA therapy on ventricular func- 
tion.‘34 Ventricular function was evaluated using 
single-plane contrast ventriculography per- 
formed immediately and prior to hospital dis- 
p < 0.002 p = ,019 
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charge. Ejection fraction and centerline-chord 
wall motion were assessed. Ejection fraction 
increased from 53% + 12% to 59% + 13% 
(P < .002) and wall motion of the infarct artery 
increased from -2.7 c 1.1 to - 1.5 c 1.7 SD 
units/chord (P < .003). Improvement in func- 
tion primarily occurred in patients who initially 
faiIed streptokinase therapy (Fig 16). Patients 
achieving streptokinase-mediated coronary re- 
canalization had no improvement in EF after 
PTCA. Since a high level of baseline EF 
(56% +: 10%) was present in this subgroup on 
admission, there was little room for subsequent 
improvement in function. 
To determine whether immediate PTCA was 
required for improved ventricular function after 
rt-PA administration, a small randomized pilot 
study was conducted at the University of Michi- 
gan.‘73 In this clinical trial, 38 patients were 
treated with 1.25 mg/kg of single-chain rt-PA 
over three hours. Therapy was initiated 3.8 f 1. I 
hours after symptom onset. After two hours of 
infusion, 84% of the infarcted arteries were 
patent, Patients with a residual stenosis >50% 
were randomized to early v delayed PTCA. Con- 
trast ventriculography was performed preinter- 
vention and 7 to 10 days post-MI. Global EF was 
unchanged for either group. Regional wall 
motion was signi~cantly improved for patients 
undergoing immediate PTCA, however, but 
unchanged for those undergoing delayed PTCA 
(Fig 17): Therefore, this pilot study suggested 
that sequential rt-PA and PTCA were required 
to achieve improved ventricular function. 
To corroborate these findings and determine 
the role and timing of PTCA, the TAM1 study 
group was organized.“’ This four-institution 
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Fig 16. Left ventricular angiogra- 
phy initially and predischarge in patients 
is presented.‘” Patients’ subgroups 
include Group A (failed thrombolytic 
therapy), Group B (successful thrombo- 
lytic therapy), and Group C (residual 
stenosis less than 50% at initial angi- 
ography). E = initial study: L = predis- 
charge study. 










Rg 17. Serial changes in gfobaI and is “5 5 
regional wall motion for patients are pre- It 
sentad.” Patients undergoing PTCA had 5 -1 0 
improved regional wall motion regardless of d 
status of arterial recanalization prior to PTCA. 1.5 
No improvement in regional motion occurred 
for patients treated with &PA alone. MO .2.5 
improvement in global function occurred for 
any group. d 5 
study enrolled 386 patients presenting within 
four hours of symptom onset. Patients were 
treated with a total dose of 150 mg single-chain 
rt-PA. After 90 minutes of drug infusion, 75% of 
infarct-reIated arteries were patent. Further- 
more, 198 patients were found to have patent 
vessels that were technically suitable for PTCA. 
Patients were randomly allocated to immediate 
or delayed PTCA. Contrast ventriculograms 
were performed pre-PTCA and at hospital dis- 
charge. No change in global EF occurred for 
either group. Regional wall motion assessed by 
the centerline-chord method was significantly 
improved for both groups. However, no differ- 
ences in changes in ventricular function were 
observed upon comparison of the two groups (Fig 
18). 
In comparing these two studies, there are two 
differences in trial design that might explain the 
discrepant findings concerning ventricular func- 
tion. First, in the pilot study all patients were 
transported to the University of Michigan prior 
to the onset of therapy. In the TAM1 Study, 
thrombolyti~ therapy was usually started in the 
emergency ward. As a result, therapy was insti- 
tuted 3.8 hours after symptom onset in the pilot 
study and 2.9 hours after symptom onset in the 
TAMI Study. Earlier initiation of therapy 
allowed for improved regional function even in 
patients treated with &-PA alone. Second, a 
five-hour maintenance infusion was used in the 
TAMI trial, but not in the pilot study. Gold et 
al”’ showed that prolonged rt-PA infusion signif- 
icantly lowers the risk of coronary reocclusion. 
Brown et aIt7’ demonstrated that signi~~ant 
ongoing thrombolysis occurs after initial angio- 
graphic patency is achieved by thrombolytic 
therapy. Thus, the prolonged infusion decreases 
reocclusion and enhances ongoing throm~lysis~ 
This therapy thereby allows improved ventricu- 
lar function to occur even when thrombolytic 
therapy alone is used. 
The discordant findings comparing the impact 
of streptokinase and PTCA v rt-PA and PTCA 
on ventricular function merit further analysis. 
After arterial patency is achieved by either rt-PA 
Fig 18. Sequential regional wail motion for patients 
in the TAMI Study’@@ who ware randomized to immedi- 
ate or deferred PTCA is prasented. EF did not improve 
for either group. Regional wall motion improved signifi- 
cantly whether PTCA was used immediately or later. 
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or strepto~nase, EF is not further improved by 
the addition of PTCA. Patients failing streptoki- 
nase do however have a major improvement in 
EF. In the Fung study,‘34 EF increased from 
49% -c 12% to 59% rt 12%, P < .002 for patients 
achieving PTCA-mediated reperfusion , after 
failed IV streptokinase therapy. In contrast to 
these findings, median global EF was initially 
52% and was 5 1% 1 week later in the 65 patients 
treated in the TAM1 Study with salvage PTCA 
after unsuccessful rt-PA therapy.‘*’ Since 30% of 
this later group had reocclusion, it is not surpris- 
ing that there was no overall increase in global 
EF. 
MORTALITY AFTER COMBINATION THERAPY 
The impact of combination therapy on mortal- 
ity can be only indirectly addressed by the TAM1 
Study. In this study a 7% hospital mortality 
occurred. Mortality was higher in patients fail- 
ing rt-PA therapy (10.4% v 5.2%). Mortality was 
especially high (55%) in patients failing both 
rt-PA and PTCA therapy. Since this study 
excluded patients in cardiogenic shock and had 
no placebo control, definitive statements regard- 
ing mortality reduction could not be made. Califf 
has now reported an 8-month follow-up of this 
patient cohort.176 A strikingly low 2% mortality 
occurred. These findings suggest that aggressive 
revascularization may dramatically decrease 
post-MI mortality. Again without a true control 
group, definitive statements regarding long-term 
mortality cannot be made from the TAM1 
Study. 
In summary, the combination of IV thrombo- 
lytic therapy and immediate PTCA has great 
promise as a reperfusion strategy. A substan- 
tially higher rate of recanalization is achieved 
than that by thrombolytic agents alone. Early 
initiation of thrombolytic therapy is useful in 
achieving prompt reperfusion. Reperfusion can 
be documents by immediate catheterization, 
and recanalization can be mechanically accom- 
plished if thrombolytic therapy has failed. Since 
reocclusion and further myocardial salvage is not 
enhanced by PTCA after successful thromboly- 
sis, the need for PTCA in these patients is less 
compelling. Ultimately, the impact of these com- 
bination strategies on mortality will be addressed 
by the NHLBI-sponsored TIM1 trial and the 
European Cooperative Study.i77 
SUMMARY OF REPERFUSION STRATEGIES 
Re~anali~atio~ Ram 
Tntracoronary streptokinase administration 
was the first well-documented method of achiev- 
ing coronary recanalization. Recanalization 
rates of 70% to 80% are expected with some time 
dependency present. Intravenous streptokinase 
achieves recanalization in up to 65% of the 
patients. A much more critical time dependency 
for eflicacy is present. After six hours of symp- 
tom duration, the recanalization rate of 30% to 
40% is identical to that spontaneously occurring. 
Although the optimal dose of rt-PA has not been 
defined, recanalization rates of 70% to 75% are 
expected with doses of rt-PA ranging from lOO- 
150 mg. There does not appear to be a temporal 
relation to efficacy for this agent. Mechanical 
recanalization with PTCA appears more effec- 
tive than thrombolytic approaches because re- 
canalization rates of 90% or more are achieved. 
Coronary reocclusion remains a problem that has 
been resolved in part by prolonged rt-PA infusion 
protocols or by the use of systemic thrombolytic 
agents in combination with early PTCA. 
Depending on the recanalization protocol used, 
recurrent ischemia and reocclusion will occur in 
10% to 30% of the patients. These events man- 
date that patients be closely observed and treated 
in centers where definitive revascularization is 
availabie. 
Thrombolytic therapy with IV or intracoro- 
nary streptokinase will improve global ventricu- 
lar function when therapy is initiated within 
three to four hours of symptom onset. Primary 
angioplasty is more effective in improving ven- 
tricular function than intracoronary streptoki- 
nase. The efficacy of PTCA alone compared to 
early IV streptokinase alone, or streptokinase in 
combination with PTCA has not been tested. To 
date, an improvement in global ventricular func- 
tion for rt-PA therapy alone or in combination 
with PTCA has not been demonstrated. The 
efficacy of rt-PA compared to placebo is cur- 
rently under study in Australia and at The Johns 
Hopkins University. Although IV rt-PA resulted 
in higher rates of coronary recanalization than 
IV streptokinase in the TIMI Study, the 
improvement in ventricular function was identi- 
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cal for the two treatment groups. Combination 
therapy with IV streptokinase and PTCA may 
result in improved EF, whereas combination 
rt-PA and PTCA does not. These two strategies 
must be formally compared in future trials. 
Comparison of the impact of various thrombo- 
fytic agents on ventricular functjon is essential, 
since my~ardial salvage may be multifa~toria1 
and not related solely to re~anaIi~tion rates. 
Impact on Mortality 
The most compelling data for improved sur- 
vival are related to IV streptokinase therapy. 
Patients most likely to benefit include those 
under age 65, with anterior MI, with the first MI 
and with KiIIip class I or II. Unfo~unatel~, 
patients at highest risk (Killip class III or IV or 
those with second MI} do not appear to benefit 
from this therapy. 
Intra~oronary stre~tokinase also appears to 
improve survival, especially if complete reperfu- 
sion is achieved. Long-term survival may be 
261 
~onting~nt on complete r~ca~ali~ation. Arterial 
patency independently appears to improve sur- 
vival irrespective of the degree of residual ven- 
tricular dysfunction. Arterial patency also pre- 
dicts improved survival after primary PTCA’@ 
or after rt-PA and PTCA therapy.‘75 Mortality is 
most likely decreased in patients of medium or 
high clinical risk. Patients at low risk do not have 
mortality reduced by myocardial reperfusion. In 
the future, accurate noninvasive methods of 
assessing myocardium at risk and detecting coro- 
nary recanalization are required. Until then, 
cardiac catheterization ofFers significant diag- 
nostic information and potentially is an avenue 
for mechanical recanalization with PTCA. These 
invasive procedures will have the most compel- 
ling indication in patients with medium or high 
clinical risk. 
Our deepest gratitude to Patricia Adkins and Joy Hagedon 
for their superb secretarial assistance in preparing this manu- 
script. 
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